Establishment and Consolidation of European Subsidiary Human Metabolome Technologies Europe B.V.
First written in FY2018-Q1. 3 of 6 entries say "Restated". Latest entry: FY2022-Q2.
No other company in this theme has enough history to compare yet.
- FY2022-Q2AchievedAnnual report
「Human Metabolome Technologies Europe B.V., formerly the sales subsidiary for the advanced research and development support business in the European market, completed its liquidation as of 29 December 2021.」
The company stated that the dissolution and liquidation of the European sales subsidiary had been completed as of 29 December 2021. - FY2021-Q3DroppedAnnual report
「Subsequently, after considering the stagnation of economic activity in Europe caused by the COVID-19 pandemic and the financial position of Human Metabolome Technologies Europe B.V., among other factors, the company examined the optimal business structure for the European market going forward. As a result, it decided to centralize management through its US subsidiary, close its sales base in Europe, and dissolve and liquidate the company.」
Regarding the European subsidiary that had been established and consolidated, disclosure was made of a planned resolution to dissolve it in September 2021 and the closure of the European sales office, indicating a policy of ending the subsidiary's operations. - FY2020RestatedAnnual report
「Human Metabolome Technologies Europe B.V. Leiden, South Holland, the Netherlands Metabolomics business 100.0」
The Dutch European sales subsidiary continues to operate as a consolidated subsidiary. - FY2019RestatedAnnual report
「Human Metabolome Technologies Europe B.V. Leiden, South Holland, the Netherlands Metabolomics business 100.0」
The European sales subsidiary continues to operate as a consolidated subsidiary. - FY2018-Q2RestatedAnnual report
「In addition, from the second quarter of the consolidated fiscal year, we included the newly established Human Metabolome Technologies Europe B.V. in the scope of consolidation.」
The company continues to state that the newly established European entity was included in the scope of consolidation from the second quarter of the consolidated fiscal year. - FY2018-Q1First statedAnnual report
「In addition, from the second quarter of the current consolidated fiscal year, we included the newly established Human Metabolome Technologies Europe B.V. in the scope of consolidation.」
The company established Human Metabolome Technologies Europe B.V. as a new entity for its European operations and included it in the scope of consolidation from the second quarter of the current consolidated fiscal year.